Loading quotes...

Forecast

There is no analyst data available for this company.

News Go to news feed

Atrys Health increases revenue in H1 2025, adjusted EBITDA falls sharply

Atrys Health raised revenue in the first half of 2025 by 7.8% to €115.8m, driven by strong oncology growth (+16.9%) and diagnostics (+9.8%), while the prevention segment stagnated. Adjusted EBITDA fell 13.3% to €21.9m, weighed down by lower R&D grants, higher drug costs and margin pressure in Portugal and Spain. Adjusted operating cash flow declined 18.2% to €15.7m; net debt stood at €163.4m with a large maturity of €142.3m in 2029. Management is focusing on higher-margin projects and is reviewing disposals to reduce debt and improve profitability. » More on de.investing.com

Financials

In the last quarter, ATRYS HEALTH S.A. EO-,01 Aktie had revenue of €77.73M and net profit of -€6.39M

(EUR)	June 2026	YoY
Revenue	77.73M	-
Gross profit	7.3M	-
Net profit	-6.39M	-
EBITDA	8.84M	-

Fundamentals

Metric	Value
Market capitalization	€198.12M
Number of shares	75.91M
52-week high/low	€3.45 - €2.31
Dividends	No
Beta	0.52
P/E ratio	-2.03
PEG ratio	0.01
P/B ratio	1.34
P/S ratio	1.97

Company profile

Atrys Health, S.A., a biomedical company, provides diagnostic services and medical treatments. The company offers diagnostic services in the fields of pathology, hematology, molecular pathology, and genetics; and diagnostic second opinion, test directory, and clinical trials and R&D services. It uses telemedicine to provide its services in the medical specialties of radiology, cardiology, ophthalmology, and dermatology. The company also provides radiotherapy; and develops therapeutic modalities and diagnostic tools. The company was formerly known as Althia Health, S.L. and changed its name to Atrys Health, S.A. in May 2016. Atrys Health, S.A. was incorporated in 2007 and is headquartered in Madrid, Spain.